linsitinib (ASP7487) / Astellas, Sling Therap  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
linsitinib (ASP7487) / Sling Therap
NCT06112340: A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Recruiting
2b
75
US
linsitinib
Sling Therapeutics, Inc.
Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto
06/26
06/26
NCT01387386: Randomized Phase II Study of Single Agent OSI-906 Versus Topotecan for Relapsed Small Cell Lung Cancer (SCLC)

Active, not recruiting
2
95
US
Topotecan, Hycamtin®, OSI-906, TKI, Tyrosine Kinase Inhibitor, Insulin Growth Factor-1 Receptor, IGF-1R, NSC-751082
H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI)
Lung Cancer
07/14
07/14
2021-005000-36: Study to Evaluate the Safety and Efficacy of Linsitinib in Patients with Active, Moderate to Severe Thyroid Eye Disease Estudio para evaluar la seguridad y eficacia del linsitinib en pacientes con enfermedad ocular tiroidea (EOT) activa y de moderada a grave.

Ongoing
2
75
Europe
Linsitinib, ASP7487, OSI-906, Film-coated tablet
VasaraGen, Inc., VasaraGen Inc.
Thyroid eye disease (TED) Enfermedad Ocular Tiroidea (EOT), Thyroid eye disease Enfermedad Ocular Tiroidea, Diseases [C] - Eye Diseases [C11]
 
 

Download Options